Management of Persistent Leukopenia

Assessment and Diagnosis

The European Hematology Association recommends performing bone marrow aspiration and biopsy in cases of persistent unexplained leukopenia to rule out underlying hematologic disorders 3
Assess for potential drug-related causes, as many medications can induce neutropenia, according to the European Society for Medical Oncology 2, 4
Consider cytogenetic analysis for patients with suspected hematologic malignancy, as suggested by the International Society for Experimental Hematology 3

For moderate leukopenia, the American Society of Hematology recommends more frequent monitoring of blood counts and considers prophylactic oral antibiotics in patients with expected prolonged, profound granulocytopenia 2, 1
Fluoroquinolones have been shown to decrease the incidence of gram-negative infection and time to first fever, according to the Infectious Diseases Society of America 1
Avoid invasive procedures due to increased risk of infection, as advised by the Centers for Disease Control and Prevention 1

For drug-induced leukopenia, the National Comprehensive Cancer Network recommends following specific dose adjustment protocols based on the medication, such as stopping treatment until ANC ≥ 1.5 × 10^9/L and platelets ≥ 75 × 10^9/L for imatinib 2, 5
Consider granulocyte colony-stimulating factor (G-CSF) therapy to increase neutrophil counts in patients with febrile severe neutropenia, as suggested by the American Society of Clinical Oncology 1

The European LeukemiaNet recommends monitoring blood counts weekly for first 4-6 weeks, then every 2 weeks or monthly until month 3, then every 3 months in chronic phase leukemia 2
More frequent monitoring for patients with advanced disease, as advised by the International Society for Experimental Hematology 2
Serial surveillance cultures may be helpful in patients with prolonged neutropenia to detect resistant organisms, according to the Infectious Diseases Society of America 1

The American Society of Hematology recommends platelet transfusions for counts ≤ 10 × 10^9/L or for patients with counts between 10-20 × 10^9/L with fever and/or infection 1
Avoid invasive procedures such as central venous catheterization, lumbar puncture, and bronchoscopy during periods of severe neutropenia, as advised by the Centers for Disease Control and Prevention 1, 7

Avoid unnecessary discontinuation of essential medications; consider dose adjustments instead of complete cessation when possible, as recommended by the National Comprehensive Cancer Network 2, 5
Remember that myelosuppression early in treatment of hematologic malignancies may be an expression of efficacy rather than true toxicity, according to the European Society for Medical Oncology 4
Don't delay empiric antibiotics in febrile neutropenia while waiting for diagnostic results, as advised by the Infectious Diseases Society of America 1